Lygos
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$150k | Grant | ||
$1.0m | Grant | ||
* | $150k | Grant | |
N/A | $550k | Grant | |
N/A | $120k | Seed | |
N/A | Seed | ||
$13.0m | Series A | ||
$14.1m | Series A | ||
$2.0m | Grant | ||
N/A | Series B | ||
N/A | $5.0m | Series B | |
* | N/A | Merger | |
Total Funding | $36.0m |
Related Content
Recent News about Lygos
EditLygos, Inc. operates as a vertically integrated provider of safe and sustainable specialty ingredients. The company leverages advanced biological and chemical tools to convert low-cost sugars into high-value products. Lygos primarily serves industries seeking bio-based alternatives to traditional chemical compounds, including the pharmaceutical, agricultural, and industrial sectors. The company’s business model revolves around the commercial-scale fermentation of bio-based cannabinoids and organic acids, such as CBG, CBC, CBD, CBDA, and CBDV, which are used in various applications from health supplements to industrial processes. By optimizing strain performance and increasing operational efficiencies, Lygos ensures the production of highly pure, consistent, and natural ingredients. Revenue is generated through the sale of these specialty ingredients to businesses looking for sustainable and economically advantageous alternatives.
Keywords: bio-based cannabinoids, fermentation, sustainable ingredients, organic acids, pharmaceutical, agricultural, industrial, strain optimization, high-value products, low-cost sugars.